肠道微生物群和多酚之间错综复杂的相互作用已成为理解和潜在利用这些生物活性化合物的治疗潜力的一个迷人前沿。酚类化合物以其抗氧化、抗炎、抗糖尿病和抗癌特性而闻名，在肠道环境中会发生复杂的转变，其中多样化的微生物生态系统对其代谢和生物利用度产生深远影响。相反，多酚表现出调节肠道微生物群的组成和活性的显着能力，促进超越单纯营养加工的双向关系。这种共生相互作用对人类健康具有重大影响，特别是在糖尿病、代谢功能障碍相关的脂肪性肝病和心血管疾病等心脏代谢疾病中。通过对分子相互作用的全面探索，这篇叙述性综述阐明了肠道微生物群和多酚之间的相互动态，揭示了心脏代谢疾病治疗干预的新途径。通过揭示这两个实体之间错综复杂的相互影响，这篇综述强调了多酚在整体健康中的多方面作用，以及肠道微生物群调节作为减轻心脏代谢疾病负担的有前途的治疗策略的关键作用。

The intricate interplay between the gut microbiota and polyphenols has emerged as a captivating frontier in understanding and potentially harnessing the therapeutic potential of these bioactive compounds. Phenolic compounds, renowned for their antioxidant, anti-inflammatory, antidiabetic, and anticancer properties, are subject to intricate transformations within the gut milieu, where the diverse microbial ecosystem exerts profound effects on their metabolism and bioavailability. Conversely, polyphenols exhibit a remarkable capacity to modulate the composition and activity of the gut microbiota, fostering a bidirectional relationship that extends beyond mere nutrient processing. This symbiotic interaction holds significant implications for human health, particularly in cardiometabolic diseases such as diabetes mellitus, metabolic-dysfunction-associated steatotic liver disease, and cardiovascular disease. Through a comprehensive exploration of molecular interactions, this narrative review elucidates the reciprocal dynamics between the gut microbiota and polyphenols, unveiling novel avenues for therapeutic intervention in cardiometabolic disorders. By unravelling the intricate cross-talk between these two entities, this review underscores the multifaceted roles of polyphenols in overall health and the pivotal role of gut microbiota modulation as a promising therapeutic strategy in mitigating the burden of cardiometabolic diseases.